Drug Lobby Driving PBS Changes, Says Expert (Australia)
This article was originally published in PharmAsia News
Australia's parliament is considering new amendments to the Pharmaceutical Benefits Scheme that will establish separate criteria for evaluating pricing of brand-name and generic drugs in Australia, and therefore affect Australian drug pricing. Australian National University expert Dr. Thomas Faunce says the amendments, if approved, will drive up brand-name drug costs. He notes that the proposed changes are backed by Australia's pharmaceutical lobby Medicines Australia. Faunce says the amendments would obviate current "reference pricing," which currently requires that new patented drugs first prove they are superior to existing products. (Click here for more
You may also be interested in...
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.